Lexaria Bioscience Corp. (NASDAQ:LEXX – Get Free Report) insider Vanessa Carle sold 2,567 shares of Lexaria Bioscience stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $4.00, for a total transaction of $10,268.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Lexaria Bioscience Trading Down 6.0 %
NASDAQ LEXX opened at $3.74 on Friday. The business has a fifty day simple moving average of $3.12 and a 200 day simple moving average of $2.92. Lexaria Bioscience Corp. has a 12 month low of $0.80 and a 12 month high of $6.85. The firm has a market capitalization of $59.13 million, a P/E ratio of -8.50 and a beta of 0.99.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Lexaria Bioscience stock. Welch Group LLC bought a new position in shares of Lexaria Bioscience Corp. (NASDAQ:LEXX – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 24,000 shares of the company’s stock, valued at approximately $87,000. Welch Group LLC owned approximately 0.19% of Lexaria Bioscience as of its most recent SEC filing. 13.06% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
View Our Latest Report on Lexaria Bioscience
Lexaria Bioscience Company Profile
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.
Recommended Stories
- Five stocks we like better than Lexaria Bioscience
- What is the Nikkei 225 index?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- The Role Economic Reports Play in a Successful Investment Strategy
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- Stock Splits, Do They Really Impact Investors?
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.